Literature DB >> 18325023

ALS patients request more information about cognitive symptoms.

P Wicks1, J Frost.   

Abstract

BACKGROUND AND
PURPOSE: Once thought to impact only voluntary motor function, ALS/Motor neuron disease (MND) is now seen as a multi-system disorder in which a minority of patients experience mild cognitive dysfunction or frontotemporal dementia. Despite clinical guidelines advocating supplying complete information to patients, educational materials on ALS often state that the mind is unaffected. We sought to establish how much patients and caregivers understand about ALS, what they have been told to expect by their physician, and if they would have appreciated more complete information.
METHODS: A two-part survey was administered online. An 'ALS quiz' gauged participants' knowledge of physical and psychological aspects of ALS. A second questionnaire assessed which symptoms patients had discussed with their clinician and explored patients' desire to receive information on psychological effects.
RESULTS: A total of 247 ALS patients and 87 caregivers participated. Participants knew less about psychological symptoms than physical ones (72% correct responses versus 82%; paired t((333)) = -5.04, P < 0.001). Patients commonly reported being told by their doctor about physical symptoms such as problems walking (85%) or stiffness/cramps (74%) but not psychological issues like emotional lability (46%) or cognitive change (11%). The majority of patients (62%) and carers (71%) indicated a desire to be informed that cognitive change or dementia might occur.
CONCLUSION: ALS is a multi-system disorder. However, despite a desire for more information from patients and their carers, healthcare professionals continue to primarily address only the physical consequences of the disease.

Entities:  

Mesh:

Year:  2008        PMID: 18325023     DOI: 10.1111/j.1468-1331.2008.02107.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Only connect: personal genomics and the future of American medicine.

Authors:  Misha Angrist
Journal:  Mol Diagn Ther       Date:  2010-04-01       Impact factor: 4.074

2.  Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course.

Authors:  Riley Bove; Elizabeth Secor; Brian C Healy; Alexander Musallam; Timothy Vaughan; Bonnie I Glanz; Emily Greeke; Howard L Weiner; Tanuja Chitnis; Paul Wicks; Philip L De Jager
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

3.  Sharing health data for better outcomes on PatientsLikeMe.

Authors:  Paul Wicks; Michael Massagli; Jeana Frost; Catherine Brownstein; Sally Okun; Timothy Vaughan; Richard Bradley; James Heywood
Journal:  J Med Internet Res       Date:  2010-06-14       Impact factor: 5.428

Review 4.  Modelling Neurological Diseases in Large Animals: Criteria for Model Selection and Clinical Assessment.

Authors:  Samantha L Eaton; Fraser Murdoch; Nina M Rzechorzek; Gerard Thompson; Claudia Hartley; Benjamin Thomas Blacklock; Chris Proudfoot; Simon G Lillico; Peter Tennant; Adrian Ritchie; James Nixon; Paul M Brennan; Stefano Guido; Nadia L Mitchell; David N Palmer; C Bruce A Whitelaw; Jonathan D Cooper; Thomas M Wishart
Journal:  Cells       Date:  2022-08-25       Impact factor: 7.666

5.  Challenges to Ethically Managing Parkinson Disease: An Interview Study of Patient Perspectives.

Authors:  Shelagh T Shaw; Pirashanthie Vivekananda-Schmidt
Journal:  J Patient Exp       Date:  2017-05-24

6.  ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Theresa Chiwera; Tom Booth; Siddharthan Chandran; Shuna Colville; Mark Heverin; Iain Mays; Suvankar Pal; Niall Pender; Marta Pinto-Grau; Ratko Radakovic; Christopher E Shaw; Laura Stephenson; Robert Swingler; Alice Vajda; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Neurology       Date:  2018-09-12       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.